FierceBiotech 28 janv. 2026 FDA puts clinical hold on Regenxbio gene therapies weeks before approval ruling
FierceBiotech 28 janv. 2026 'We have an expansive view:' Kardigan CEO knits sharper trials, digital health into cardio strategy
FierceBiotech 28 janv. 2026 With 200 JPM meetings, Novo Nordisk BD head searches for the next Metsera
FierceBiotech 27 janv. 2026 Rethinking heart attacks as nervous system gone haywire sparks potential new drug targets
FierceBiotech 27 janv. 2026 TD Cowen picks top 3 medtech prospects across its ‘Bones, Bots, and No More Shots’ portfolio
FierceBiotech 27 janv. 2026 'AI-native' outpatient surgery startup Oath Surgical inks Nvidia partnership
FierceBiotech 27 janv. 2026 United Therapeutics' bioengineered temporary liver shows promise in phase 1 trial
FierceBiotech 27 janv. 2026 From gene therapies to … firearms? Italian biotech makes unexpected strategic pivot
FierceBiotech 27 janv. 2026 Lisata reclaims China rights to solid tumor candidate ahead of acquisition
FierceBiotech 27 janv. 2026 After patient death, FDA lifts hold on 1 of 2 late-stage trials testing Intellia’s CRISPR therapy
FierceBiotech 27 janv. 2026 Qilu programs path into cardiometabolic disease with $120M, AI-enabled Insilico alliance
FierceBiotech 26 janv. 2026 Ex-CytoDyn CEO sentenced to prison, must pay $5.3M restitution as former CRO leader wins new trial
FierceBiotech 26 janv. 2026 European investment firm Gimv calls it quits on new life science financing
FierceBiotech 26 janv. 2026 Guardant Health gets FDA nod to expand use of blood test for colon cancer